Cargando…

Formulating a Stable Mannitol Infusion while Maintaining Hyperosmolarity

Mannitol infusion is commonly used in the treatment of intracranial hypertension following traumatic brain injury. It has long been known to have stability issues, specifically, mannitol recrystallises from solutions greater than 10% w/v in ambient conditions. This can happen at any time, whether on...

Descripción completa

Detalles Bibliográficos
Autores principales: Kavanagh, Oisín, Hogan, Fiona, Murphy, Caoimhe, Croker, Denise, Walker, Gavin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076636/
https://www.ncbi.nlm.nih.gov/pubmed/32098214
http://dx.doi.org/10.3390/pharmaceutics12020187
_version_ 1783507252949286912
author Kavanagh, Oisín
Hogan, Fiona
Murphy, Caoimhe
Croker, Denise
Walker, Gavin
author_facet Kavanagh, Oisín
Hogan, Fiona
Murphy, Caoimhe
Croker, Denise
Walker, Gavin
author_sort Kavanagh, Oisín
collection PubMed
description Mannitol infusion is commonly used in the treatment of intracranial hypertension following traumatic brain injury. It has long been known to have stability issues, specifically, mannitol recrystallises from solutions greater than 10% w/v in ambient conditions. This can happen at any time, whether on the pharmacy shelf or during a medical procedure. This study describes the stability limits of 20% w/v mannitol infusion (the most common strength used clinically) and proposes a number of safer, stable and tuneable hyperosmotic formulations of mannitol in combination with clinically acceptable osmotic agents (NaCl, sorbitol and glycerol).
format Online
Article
Text
id pubmed-7076636
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70766362020-03-20 Formulating a Stable Mannitol Infusion while Maintaining Hyperosmolarity Kavanagh, Oisín Hogan, Fiona Murphy, Caoimhe Croker, Denise Walker, Gavin Pharmaceutics Communication Mannitol infusion is commonly used in the treatment of intracranial hypertension following traumatic brain injury. It has long been known to have stability issues, specifically, mannitol recrystallises from solutions greater than 10% w/v in ambient conditions. This can happen at any time, whether on the pharmacy shelf or during a medical procedure. This study describes the stability limits of 20% w/v mannitol infusion (the most common strength used clinically) and proposes a number of safer, stable and tuneable hyperosmotic formulations of mannitol in combination with clinically acceptable osmotic agents (NaCl, sorbitol and glycerol). MDPI 2020-02-21 /pmc/articles/PMC7076636/ /pubmed/32098214 http://dx.doi.org/10.3390/pharmaceutics12020187 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Kavanagh, Oisín
Hogan, Fiona
Murphy, Caoimhe
Croker, Denise
Walker, Gavin
Formulating a Stable Mannitol Infusion while Maintaining Hyperosmolarity
title Formulating a Stable Mannitol Infusion while Maintaining Hyperosmolarity
title_full Formulating a Stable Mannitol Infusion while Maintaining Hyperosmolarity
title_fullStr Formulating a Stable Mannitol Infusion while Maintaining Hyperosmolarity
title_full_unstemmed Formulating a Stable Mannitol Infusion while Maintaining Hyperosmolarity
title_short Formulating a Stable Mannitol Infusion while Maintaining Hyperosmolarity
title_sort formulating a stable mannitol infusion while maintaining hyperosmolarity
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076636/
https://www.ncbi.nlm.nih.gov/pubmed/32098214
http://dx.doi.org/10.3390/pharmaceutics12020187
work_keys_str_mv AT kavanaghoisin formulatingastablemannitolinfusionwhilemaintaininghyperosmolarity
AT hoganfiona formulatingastablemannitolinfusionwhilemaintaininghyperosmolarity
AT murphycaoimhe formulatingastablemannitolinfusionwhilemaintaininghyperosmolarity
AT crokerdenise formulatingastablemannitolinfusionwhilemaintaininghyperosmolarity
AT walkergavin formulatingastablemannitolinfusionwhilemaintaininghyperosmolarity